Skip to main content

Table 2 Summarized of grade 3 or greater adverse events

From: Effect of neoadjuvant chemotherapy in patients with gastric cancer: a PRISMA-compliant systematic review and meta-analysis

Outcomes NAC group Control group RR (95% CI) P value P value for heterogeneity
Granulocytopenia 67/222 52/240 1.23 (0.81–1.87) 0.338 0.209
Lymphocytopenia 46/204 23/230 2.02 (1.27–3.24) 0.003
Leukopenia 39/250 29/263 1.26 (0.59–2.66) 0.552 0.086
Hemoglobinopathy 11/239 1/252 11.13 (1.45–85.58) 0.021
Thrombocytopenia 2/287 6/286 0.35 (0.07–1.72) 0.195 0.677
Other hematologic abnormality 1/249 2/251 0.51 (0.05–5.55) 0.577
Nausea 25/264 29/263 0.86 (0.53–1.41) 0.559 0.889
Vomiting 13/237 14/239 0.94 (0.45–1.96) 0.868
Neurologic effects 10/279 7/285 1.46 (0.55–3.89) 0.453 0.329
Skin effects 8/242 2/251 4.05 (0.87–18.88) 0.075
Stomatitis 10/240 5/248 2.02 (0.70–5.84) 0.192
Diarrhea 6/244 5/248 1.21 (0.38–3.93) 0.746